{
  "docId": "019de077-2202-715b-adea-57c1f9ae9ce5",
  "docSlug": "719db50244a96da2bbf79cc8f7d91684",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 26 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 26,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-2202-715b-adea-57c1f9ae9ce5/11",
  "deckHref": "/decks/019de077-2202-715b-adea-57c1f9ae9ce5",
  "deckJsonHref": "/decks/019de077-2202-715b-adea-57c1f9ae9ce5.json",
  "deckAnchorHref": "/decks/019de077-2202-715b-adea-57c1f9ae9ce5#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.88,
        "x": 0.06,
        "y": 0.74
      },
      "kind": "callout",
      "text": "Imdusiran 60 mg every 8 weeks for 24 to 48 weeks selected for Phase 2 trials",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "acd754f5-b6f9-4a12-9296-71380e6147ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.23,
        "x": 0.02,
        "y": 0.29
      },
      "kind": "list",
      "text": "Imdusiran was generally safe and well-tolerated after completing dosing in over 40 CHB patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2dade681-3ec8-4fb2-9ee8-f23e0f9a5901",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.23,
        "x": 0.52,
        "y": 0.29
      },
      "kind": "list",
      "text": "A reduction in HBsAg and HBV DNA was sustained in the majority of patients that stopped all treatments",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91b83e23-19b3-4285-98a8-f668140759e4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.23,
        "x": 0.27,
        "y": 0.29
      },
      "kind": "list",
      "text": "Imdusiran provided robust and comparable HBsAg declines regardless of dose, dosing interval, HBeAg or DNA status",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef8df97d-1c4d-4050-a857-ebc6ade0e837",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.23,
        "x": 0.77,
        "y": 0.29
      },
      "kind": "list",
      "text": "Imdusiran results in HBV-specific T-cell immune restoration and decrease of exhausted T-cells in some patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f08e025c-4cc3-4bf8-9f3a-b467feec416d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "AB-729-001 Phase 1a/1b Clinical Trial: Key Takeaways",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a1ec63f-afdc-4a09-b51f-d954b0f43e3d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "ab082675-e3a6-46ea-9484-817f8ace52c0",
      "evidence": "The slide presents information in a list/bullet format, indicating a list presentation.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 11,
      "from": 11,
      "beatId": "e153389a-d707-48de-97dd-4aa6c973fe23",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Key Takeaways",
      "beatSlug": null,
      "evidence": "The document highlights key takeaways from clinical trials.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}